Rifaximin alters gut microbiota profile, but does not affect systemic inflammation - a randomized controlled trial in common variable immunodeficiency-Reference-Cited by-同舟云学术

Rifaximin alters gut microbiota profile, but does not affect systemic inflammation - a randomized controlled trial in common variable immunodeficiency

Published:2019-01-17 Issue:1 Volume:9 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Jørgensen S. F.,Macpherson M. E.,Bjørnetrø T.,Holm K.,Kummen M.,Rashidi A.,Michelsen A. E.,Lekva T.^ORCID,Halvorsen B.,Trøseid M.,Mollnes T. E.,Berge R. K.,Yndestad A.,Ueland T.,Karlsen T. H.,Aukrust P.,Hov J. R.^ORCID,Fevang B.

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-018-35367-7.pdf

Reference28 articles.

1. Luczynski, P. et al. Growing up in a Bubble: Using Germ-Free Animals to Assess the Influence of the Gut Microbiota on Brain and Behavior. Int. J. Neuropsychopharmacol. 19, pyw020, https://doi.org/10.1093/ijnp/pyw020 (2016).

2. Turnbaugh, P. J. et al. A core gut microbiome in obese and lean twins. Nature 457, 480–484, https://doi.org/10.1038/nature07540 (2009).

3. Giongo, A. et al. Toward defining the autoimmune microbiome for type 1 diabetes. ISME J 5, 82–91, https://doi.org/10.1038/ismej.2010.92 (2011).

4. Kelly, T. N. et al. Gut Microbiome Associates With Lifetime Cardiovascular Disease Risk Profile Among Bogalusa Heart Study Participants. Circ. Res. 119, 956–+, https://doi.org/10.1161/Circresaha.116.309219 (2016).

5. Vazquez-Castellanos, J. F. et al. Altered metabolism of gut microbiota contributes to chronic immune activation in HIV-infected individuals. Mucosal Immunol. 8, 760–772, https://doi.org/10.1038/mi.2014.107 (2015).

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Retraction Note: Rifaximin alters gut microbiota profile, but does not affect systemic inflammation - a randomized controlled trial in common variable immunodeficiency;Scientific Reports;2024-02-14

2. Clinical and experimental treatment of primary humoral immunodeficiencies;Clinical and Experimental Immunology;2024-02-02

3. Management of liver disease and portal hypertension in common variable immunodeficiency (CVID);JHEP Reports;2023-11

4. A relational framework for microbiome research with Indigenous communities;Nature Microbiology;2023-09-28

5. Disturbed lipid profile in common variable immunodeficiency – a pathogenic loop of inflammation and metabolic disturbances;Frontiers in Immunology;2023-07-20